UroGen Pharma Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
UroGen Pharma Ltd. (URGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $2.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-02
- UroGen Pharma Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $2.10M, a 950.00% increase from fiscal 2024.
- UroGen Pharma Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $200.00K, a 71.43% decline from fiscal 2023.
- UroGen Pharma Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $700.00K, a 12.50% decline from fiscal 2022.
- UroGen Pharma Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $800.00K, a 300.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|
| 2025-12-31 | $2.10M 10-K · filed 2026-03-02 | |
| 2024-12-31 | $200.00K 10-K · filed 2025-03-10 | $200.00K 10-K · filed 2026-03-02 |
| 2023-12-31 | $700.00K 10-K · filed 2025-03-10 | |
| 2022-12-31 | $800.00K 10-K · filed 2024-03-14 | |
| 2021-12-31 | $200.00K 10-K · filed 2023-03-24 | |
| 2020-12-31 | $2.30M 10-K · filed 2022-03-21 | |
| 2019-12-31 | $14.20M 10-K · filed 2021-03-18 | |
| 2018-12-31 | $31.60M 10-K · filed 2020-03-02 | |
| 2017-12-31 | $21.40M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |